Received Dec 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | F95HB | — |
received first dose of Twinrix on October 2025, and late second dose on December 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received HAB (Twinrix) (batch number F95HB, expiry date 29-MAY-2028) for prophylaxis. Concomitant products included HEPATITIS A VACCINE INACT;HEPATITIS B VACCINE RHBSAG (YEAST) (TWINRIX). In DEC-2025, the patient received the 2nd dose of Twinrix. In DEC-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: received first dose of Twinrix on October 2025, and late second dose on December 2025). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date 10-DEC-2025 The pharmacist mentioned that a patient received late second dose on December 2025 (specific dates unknown). The reporter did not want to provide patient initials or date of birth of the patient.
TWINRIX